Intelligence Profile
Safety Profile
Safety Profile of Testosterone Cypionate
Known Side Effects
Based on available evidence, testosterone cypionate carries several documented safety concerns:
Cardiovascular Events: A 2026 pharmacovigilance study specifically identified myocardial infarction, pulmonary embolism, and deep vein thrombosis following testosterone cypionate use, indicating serious cardiovascular and thromboembolic risks.
Erythrocytosis: Evidence shows testosterone cypionate can cause erythrocytosis (elevated red blood cell count). A 2025 randomized controlled pilot study specifically examined this effect in transgender men, suggesting it's a recognized complication requiring monitoring.
Injection Site Reactions: As with any injectable medication, local reactions at injection sites may occur, though specific data on frequency is not provided in the available evidence.
Contraindications and Special Populations
Prostate Cancer: The evidence presents conflicting perspectives on testosterone use in prostate cancer survivors. While one 2026 randomized clinical trial examined testosterone treatment in prostate cancer survivors with hypogonadism, suggesting some clinical consideration of this population, traditional contraindications for testosterone therapy typically include active or history of prostate cancer. The safety in this population requires careful individual assessment.
Cardiovascular Disease: Given the documented cardiovascular risks including myocardial infarction and thromboembolism, patients with existing cardiovascular disease or risk factors warrant careful evaluation before treatment initiation.
Monitoring Requirements
The available evidence suggests several parameters require monitoring:
- Regular assessment for signs of cardiovascular events
- Monitoring for erythrocytosis through periodic blood counts
- Ongoing evaluation of symptom stability as referenced in primary care management protocols
Drug Interactions
The provided evidence does not contain specific information about drug interactions with testosterone cypionate. This represents a significant gap in the available data.
Evidence Limitations
Important Note: The evidence base for this safety profile is limited. Several key areas lack comprehensive data:
- Complete adverse event profiles and their frequencies
- Detailed contraindication lists
- Comprehensive drug interaction data
- Long-term safety outcomes
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients should consult healthcare providers for personalized medical decisions regarding testosterone cypionate therapy.
The safety profile presented here is based on limited available evidence and may not capture all potential risks or considerations for testosterone cypionate use.